Sign in

CIK 0001549595

  • Large accelerated filer

Nurix Therapeutics, Inc.

Sign in to watch
Ticker
NRIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Nov 30
Incorporated
DE
Entity type
Operating
EIN
270838048
Phone
+1 415-660-5320
Business address
1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Former names
Nurix, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,712,859
in 10 filings, $1.0M under 10b5-1 plans

Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 1 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-02-18 van Houte Hans Chief Financial Officer Sale −3,140 $34.24 $108K 10,443
2021-02-18 van Houte Hans Chief Financial Officer Sale −3,652 $35.10 $128K 6,791
2021-02-18 van Houte Hans Chief Financial Officer Sale −5,725 $36.00 $206K 1,066
2021-02-18 van Houte Hans Chief Financial Officer Sale −666 $36.91 $25K 400
2021-02-18 van Houte Hans Chief Financial Officer Sale −400 $38.05 $15K 0
2021-02-18 van Houte Hans Chief Financial Officer Exercise or conversion · Employee Stock Option (right to buy) −13,583 69,750
2021-02-18 Ring Christine General Counsel Exercise or conversion +2,000 $1.86 $4K 2,000
2021-02-18 Ring Christine General Counsel Sale −400 $34.48 $14K 1,600
2021-02-18 Ring Christine General Counsel Sale −1,100 $35.86 $39K 500
2021-02-18 Ring Christine General Counsel Sale −500 $37.03 $19K 0
2021-02-18 Ring Christine General Counsel Exercise or conversion · Employee Stock Option (right to buy) −2,000 119,666
2021-02-18 Hansen Gwenn Chief Scientific Officer Exercise or conversion +800 $7.26 $6K 12,800
2021-02-18 Hansen Gwenn Chief Scientific Officer Sale −600 $35.81 $21K 12,200
2021-02-18 Hansen Gwenn Chief Scientific Officer Sale −200 $37.67 $8K 12,000
2021-02-18 Hansen Gwenn Chief Scientific Officer Exercise or conversion · Employee Stock Option (right to buy) −800 75,866
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion +9,107 $0.84 $8K 9,107
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion +3,797 $7.26 $28K 12,904
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion +2,096 $9.57 $20K 15,000
2021-02-18 Beaurang Pierre Chief Business Officer Sale −2,647 $34.19 $90K 12,353
2021-02-18 Beaurang Pierre Chief Business Officer Sale −4,553 $35.02 $159K 7,800

Page 39 of 42 · 829 trades